Replication - why we need to publish our findings

被引:10
|
作者
Curtis, Michael J. [1 ]
Abernethy, Darrell R. [2 ,3 ]
机构
[1] Kings Coll London, St Thomas Hosp, Rayne Inst, Cardiovasc Div, London SE1 7EH, England
[2] US FDA, Off Clin Pharmacol, Silver Spring, MD 20903 USA
[3] Off Translat Sci Sci, Silver Spring, MD 20903 USA
来源
关键词
Experimental design; replication;
D O I
10.1002/prp2.164
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacology research sector is changing to accommodate a need for greater transparency and better standards. The themed articles contained herein explain how Pharmacology Research and Perspectives (PR&P) has responded to this agenda. This issue of PR&P contains three articles that consider the reliability of pharmacological research publications, and approaches to their improvement in this regard. This first article explains the importance of publishing findings that confirm or repudiate published findings (so called "replication" studies). It also emphasizes that PR&P actively encourages submission of such articles, and seeks to oppose the publication bias that favors publication of "positive" findings. The second paper explores some initiatives to publish "negative" clinical findings, including a PR&P initiative. The final paper elaborates a toolkit that can be applied to drug discovery research to facilitate the reliability of findings.
引用
收藏
页数:5
相关论文
共 50 条